{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T17:05:41Z","timestamp":1784307941960,"version":"3.55.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Clinical Research Project of Changzhou Medical Center of Nanjing Medical University","award":["(CMCC202309)"],"award-info":[{"award-number":["(CMCC202309)"]}]},{"name":"Science and Technology Project of Changzhou Health Commission","award":["\uff08ZD202336\uff09"],"award-info":[{"award-number":["\uff08ZD202336\uff09"]}]},{"name":"The Top Talent of Changzhou \u201cThe 14th Five-Year Plan\u201d High-Level Health Talents Training Project","award":["(2022CZBJ051)"],"award-info":[{"award-number":["(2022CZBJ051)"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-024-03524-0","type":"journal-article","created":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T06:44:32Z","timestamp":1732603472000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Effectiveness and safety of vonoprazan and amoxicillin dual regimen with Saccharomyces boulardii supplements on eradication of Helicobacter pylori"],"prefix":"10.1186","volume":"24","author":[{"given":"Jing","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizhou","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,26]]},"reference":[{"key":"3524_CR1","doi-asserted-by":"crossref","unstructured":"Man S, Ma Y, Jin C et al. Association between Helicobacter pylori Infection and Diabetes: A Cross-Sectional Study in China. J Diabetes Res. 2020; 2020: 7201379.","DOI":"10.1155\/2020\/7201379"},{"key":"3524_CR2","doi-asserted-by":"publisher","first-page":"632","DOI":"10.3390\/nu14030632","volume":"14","author":"N Viazis","year":"2022","unstructured":"Viazis N, Argyriou K, Kotzampassi K, et al. A four-Probiotics Regimen combined with a standard Helicobacter Pylori-Eradication Treatment reduces Side effects and increases eradication rates. Nutrients. 2022;14:632.","journal-title":"Nutrients"},{"key":"3524_CR3","doi-asserted-by":"crossref","unstructured":"Doorakkers E, Lagergren J, Engstrand L et al. Helicobacter pylori eradication treatment and the risk of gastric adenocarcinoma in a western population. Gut; 67: 2092\u20136.","DOI":"10.1136\/gutjnl-2017-315363"},{"key":"3524_CR4","doi-asserted-by":"crossref","unstructured":"Malfertheiner P, Megraud F, Rokkas T et al. European Helicobacter and Microbiota Study group. Management of Helicobacter pylori infection: the Maastricht VI\/Florence consensus report. Gut. 2022:gutjnl\u20132022.","DOI":"10.1136\/gutjnl-2022-327745"},{"key":"3524_CR5","doi-asserted-by":"publisher","first-page":"e12475","DOI":"10.1111\/hel.12475","volume":"23","author":"WZ Liu","year":"2018","unstructured":"Liu WZ, Xie Y, Lu H, et al. Chinese Society of Gastroenterology, Chinese Study Group on Helicobacter pylori and Peptic Ulcer. Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection. Helicobacter. 2018;23:e12475.","journal-title":"Helicobacter"},{"key":"3524_CR6","doi-asserted-by":"publisher","first-page":"437","DOI":"10.14309\/ajg.0000000000000132","volume":"114","author":"J Yang","year":"2019","unstructured":"Yang J, Zhang Y, Fan L, et al. Eradication efficacy of modified dual therapy compared with Bismuth-Containing Quadruple Therapy as a first-line treatment of Helicobacter pylori. Am J Gastroenterol. 2019;114:437\u201345.","journal-title":"Am J Gastroenterol"},{"key":"3524_CR7","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/phar.2662","volume":"42","author":"JL Guan","year":"2022","unstructured":"Guan JL, Hu YL, An P, et al. Comparison of high-dose dual therapy with bismuth-containing quadruple therapy in Helicobacter pylori-infected treatment-naive patients: an open-label, multicenter, randomized controlled trial. Pharmacotherapy. 2022;42:224\u201332.","journal-title":"Pharmacotherapy"},{"key":"3524_CR8","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1007\/s10620-017-4536-8","volume":"62","author":"Y Hu","year":"2017","unstructured":"Hu Y, Zhu Y, Lu NH. Primary antibiotic resistance of Helicobacter pylori in China. Dig Dis Sci. 2017;62:1146\u201354.","journal-title":"Dig Dis Sci"},{"key":"3524_CR9","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s13756-019-0632-1","volume":"8","author":"DS Liu","year":"2019","unstructured":"Liu DS, Wang YH, Zhu ZH, et al. Characteristics of Helicobacter pylori antibiotic resistance: data from four different populations. Antimicrob Resist Infect Control. 2019;8:192.","journal-title":"Antimicrob Resist Infect Control"},{"key":"3524_CR10","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/BF02116532","volume":"14","author":"YJ Debets-Ossenkopp","year":"1995","unstructured":"Debets-Ossenkopp YJ, Namavar F, MacLaren DM. Effect of an acidic environment on the susceptibility of Helicobacter pylori to trospectomycin and other antimicrobial agents. Eur J Clin Microbiol Infect Dis. 1995;14:353\u20135.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"3524_CR11","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1128\/AAC.40.5.1327","volume":"40","author":"PD Midolo","year":"1996","unstructured":"Midolo PD, Turnidge JD, Munckhof WJ. Is bactericidal activity of Amoxicillin against Helicobacter pylori concentration dependent? Antimicrob Agents Chemother. 1996;40:1327\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"3524_CR12","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1111\/apt.13325","volume":"42","author":"Y Sakurai","year":"2015","unstructured":"Sakurai Y, Mori Y, Okamoto H, et al. Acid-inhibitory effects of vonoprazan 20\u00a0mg compared with esomeprazole 20\u00a0mg or rabeprazole 10\u00a0mg in healthy adult male subjects\u2013a randomised open-label cross-over study. Aliment Pharmacol Ther. 2015;42:719\u201330.","journal-title":"Aliment Pharmacol Ther"},{"key":"3524_CR13","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1007\/s00535-020-01723-6","volume":"55","author":"H Okubo","year":"2020","unstructured":"Okubo H, Akiyama J, Kobayakawa M, et al. Vonoprazan-based triple therapy is effective for Helicobacter pylori eradication irrespective of clarithromycin susceptibility. J Gastroenterol. 2020;55:1054\u201361.","journal-title":"J Gastroenterol"},{"key":"3524_CR14","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1007\/s00535-020-01709-4","volume":"55","author":"T Gotoda","year":"2020","unstructured":"Gotoda T, Kusano C, Suzuki S, et al. Clinical impact of vonoprazan-based dual therapy with Amoxicillin for H. Pylori infection in a treatment-na\u00efve cohort of junior high school students in Japan. J Gastroenterol. 2020;55:969\u201376.","journal-title":"J Gastroenterol"},{"key":"3524_CR15","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1136\/gutjnl-2019-319954","volume":"69","author":"S Suzuki","year":"2020","unstructured":"Suzuki S, Gotoda T, Kusano C, et al. Seven-day vonoprazan and low-dose Amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan. Gut. 2020;69:1019\u201326.","journal-title":"Gut"},{"key":"3524_CR16","doi-asserted-by":"crossref","unstructured":"Hu Y, Xu X, Ouyang YB et al. Optimization of Vonoprazan-Amoxicillin dual therapy for eradicating Helicobacter pyloriinfection in China: a prospective, randomized clinical pilot study. Helicobacter. 2022: e12896.","DOI":"10.1111\/hel.12896"},{"key":"3524_CR17","doi-asserted-by":"publisher","first-page":"987","DOI":"10.21037\/atm-22-4133","volume":"10","author":"Y Lin","year":"2022","unstructured":"Lin Y, Xu H, Yun J, et al. The efficacy of vonoprazan combined with different dose Amoxicillin on eradication of Helicobacter pylori: an open, multicenter, randomized clinical study. Ann Transl Med. 2022;10:987.","journal-title":"Ann Transl Med"},{"key":"3524_CR18","doi-asserted-by":"publisher","first-page":"e12651","DOI":"10.1111\/hel.12651","volume":"24","author":"BG Zhou","year":"2019","unstructured":"Zhou BG, Chen LX, Li B, et al. Saccharomyces boulardii as an adjuvant therapy for Helicobacter pylori eradication: a systematic review and meta-analysis with trial sequential analysis. Helicobacter. 2019;24:e12651.","journal-title":"Helicobacter"},{"key":"3524_CR19","doi-asserted-by":"crossref","unstructured":"Schulz KF, Altman DG, Moher D, for the CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials.","DOI":"10.1016\/j.ijsu.2010.09.006"},{"key":"3524_CR20","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJM198710223171717","volume":"317","author":"RD Mosteller","year":"1987","unstructured":"Mosteller RD. Simplified calculation of body-surface area. N Engl J Med. 1987;317:1098.","journal-title":"N Engl J Med"},{"key":"3524_CR21","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1080\/00365521.2016.1250157","volume":"52","author":"Y Kajihara","year":"2017","unstructured":"Kajihara Y, Shimoyama T, Mizuki I. Analysis of the cost-effectiveness of using Vonoprazan-Amoxicillin-clarithromycin triple therapy for first-line Helicobacter pylori eradication. Scand J Gastroenterol. 2017;52:238\u201341.","journal-title":"Scand J Gastroenterol"},{"key":"3524_CR22","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1159\/000502287","volume":"101","author":"T Furuta","year":"2020","unstructured":"Furuta T, Yamade M, Kagami T, et al. Dual therapy with Vonoprazan and Amoxicillin is as effective as Triple Therapy with Vonoprazan, Amoxicillin and Clarithromycin for Eradication of Helicobacter pylori. Digestion. 2020;101:743\u201351.","journal-title":"Digestion"},{"key":"3524_CR23","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1111\/jgh.15572","volume":"36","author":"T Horii","year":"2021","unstructured":"Horii T, Suzuki S, Takano C, et al. Lower impact of Vonoprazan-Amoxicillin dual therapy on gut microbiota for Helicobacter pylori eradication. J Gastroenterol Hepatol. 2021;36:3314\u201321.","journal-title":"J Gastroenterol Hepatol"},{"key":"3524_CR24","doi-asserted-by":"publisher","first-page":"965","DOI":"10.12669\/pjms.38.4.5436","volume":"38","author":"BF Zuberi","year":"2022","unstructured":"Zuberi BF, Ali FS, Rasheed T, et al. Comparison of Vonoprazan and Amoxicillin Dual Therapy with Standard Triple Therapy with Proton Pump Inhibitor for Helicobacter Pylori eradication: a Randomized Control Trial. Pak J Med Sci. 2022;38:965\u20139.","journal-title":"Pak J Med Sci"},{"key":"3524_CR25","unstructured":"Chey WD, M\u00e9graud F, Laine L et al. Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the US and Europe: Randomized Clinical Trial. Gastroenterology. 2022: S0016-5085(22)00609-6."},{"key":"3524_CR26","doi-asserted-by":"publisher","first-page":"e12788","DOI":"10.1111\/hel.12788","volume":"26","author":"H Eto","year":"2021","unstructured":"Eto H, Suzuki S, Kusano C, et al. Impact of body size on first-line Helicobacter pylori eradication success using Vonoprazan and Amoxicillin dual therapy. Helicobacter. 2021;26:e12788.","journal-title":"Helicobacter"},{"key":"3524_CR27","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/jcph.195","volume":"54","author":"T Furuta","year":"2014","unstructured":"Furuta T, Sugimoto M, Yamade M, et al. Effect of dosing schemes of Amoxicillin on eradication rates of Helicobacter pylori with Amoxicillin-based triple therapy. J Clin Pharmacol. 2014;54:258\u201366.","journal-title":"J Clin Pharmacol"},{"key":"3524_CR28","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1111\/apm.12237","volume":"122","author":"S Sakarya","year":"2014","unstructured":"Sakarya S, Gunay N. Saccharomyces boulardii expresses neuraminidase activity selective for \u03b12,3-linked sialic acid that decreases Helicobacter pylori adhesion to host cells. APMIS. 2014;122:941\u201350.","journal-title":"APMIS"},{"key":"3524_CR29","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.3748\/wjg.v16.i18.2202","volume":"16","author":"LV McFarland","year":"2010","unstructured":"McFarland LV. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol. 2010;16:2202\u201322.","journal-title":"World J Gastroenterol"},{"key":"3524_CR30","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/S0140-6736(09)60743-1","volume":"375","author":"ME Falagas","year":"2010","unstructured":"Falagas ME, Karageorgopoulos DE. Adjustment of dosing of antimicrobial agents for bodyweight in adults. Lancet. 2010;375:248\u201351.","journal-title":"Lancet"},{"key":"3524_CR31","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ijantimicag.2016.01.009","volume":"47","author":"AS Alobaid","year":"2016","unstructured":"Alobaid AS, Hites M, Lipman J, et al. Effect of obesity on the pharmacokinetics of antimicrobials in critically ill patients: a structured review. Int J Antimicrob Agents. 2016;47:259\u201368.","journal-title":"Int J Antimicrob Agents"},{"key":"3524_CR32","doi-asserted-by":"publisher","first-page":"e12876","DOI":"10.1111\/hel.12876","volume":"27","author":"QQ Shao","year":"2022","unstructured":"Shao QQ, Yu XC, Yu M, et al. Rabeprazole plus Amoxicillin dual therapy is equally effective to bismuth-containing quadruple therapy for Helicobacter pylori eradication in central China: a single-center, prospective, open-label, randomized-controlled trial. Helicobacter. 2022;27:e12876.","journal-title":"Helicobacter"},{"key":"3524_CR33","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1136\/gut.26.12.1327","volume":"26","author":"F Parente","year":"1985","unstructured":"Parente F, Lazzaroni M, Sangaletti O, et al. Cigarette smoking, gastric acid secretion, and serum pepsinogen I concentrations in duodenal ulcer patients. Gut. 1985;26:1327\u201332.","journal-title":"Gut"},{"key":"3524_CR34","doi-asserted-by":"publisher","first-page":"10338","DOI":"10.3748\/wjg.v20.i30.10338","volume":"20","author":"J Molina-Infante","year":"2014","unstructured":"Molina-Infante J, Gisbert JP. Optimizing clarithromycin-containing therapy for Helicobacter pylori in the era of antibiotic resistance. World J Gastroenterol. 2014;20:10338\u201347.","journal-title":"World J Gastroenterol"},{"key":"3524_CR35","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/0016-5085(94)90138-4","volume":"107","author":"K Endoh","year":"1994","unstructured":"Endoh K, Leung FW. Effects of smoking and nicotine on the gastric mucosa: a review of clinical and experimental evidence. Gastroenterology. 1994;107:864\u201378.","journal-title":"Gastroenterology"},{"key":"3524_CR36","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1080\/14622200801908190","volume":"10","author":"J Shuter","year":"2008","unstructured":"Shuter J, Bernstein SL. Cigarette smoking is an independent predictor of nonadherence in HIV-infected individuals receiving highly active antiretroviral therapy. Nicotine Tob Res. 2008;10:731\u20136.","journal-title":"Nicotine Tob Res"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-024-03524-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-024-03524-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-024-03524-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T08:07:12Z","timestamp":1732608432000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-024-03524-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,26]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3524"],"URL":"https:\/\/doi.org\/10.1186\/s12876-024-03524-0","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,26]]},"assertion":[{"value":"10 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was reviewed and approved by the Clinical Medical Technical Ethics Committee of the Affiliated Changzhou No. 2 People\u2019s Hospital of Nanjing Medical University (No. [2021] YLJSC016).This study is registered at Chinese Clinical trial Registry. The registration identification number is ChiCTR2100055101.All study participants provided informed written consent prior to study enrollment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"430"}}